Inflammation News and Research

RSS

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Vitamin D rich food source for winter - Wild Alaska salmon

Today is the shortest day of the year. During the dark winter months, sunlight can be an insufficient source of vitamin D which is vital for the absorption of calcium and phosphorous. Low vitamin D levels have recently been linked to a greater chance of developing diseases including diabetes and heart disease, several cancers and the common cold.

21 Dec 2009

Headache on rare occasions can be a warning sign of potentially serious disorder

Headaches are extremely common. Almost everyone has experienced a severe headache at least once in his or her lifetime. In most cases, headaches are minor nuisances that resolve within a short time. However, a headache can on rare occasions be the warning sign of a potentially serious disorder that requires immediate medical attention.

19 Dec 2009

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

American Oriental Bioengineering, Inc., ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that 158 of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC").

19 Dec 2009

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Immuno Laboratories, a leading provider of food and environmental allergy testing services, announced an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States.

18 Dec 2009

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals, Inc., today announced the Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Prophylactic misuse of NSAIDs cause more harm than good

Athletes' superstitions and rituals can help them get psyched up for contests, but when these rituals involve non-steroidal anti-inflammatory drugs (NSAIDs), which many athletes gobble down before and during events, they could be causing more harm than good.

17 Dec 2009

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease, say scientists.

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

Majority of Canadians confuse sinusitis with H1N1 symptoms

It's winter, that great Canadian season of snow, ice, grey skies...and colds and the flu. In a year when H1N1 is high on everyone's radar, it is more important than ever for Canadians to know what their symptoms mean and when they should see their doctor.

17 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

Cohera Medical announces treatment of first patient in TissuGlu study

Cohera Medical Inc. today announced the treatment of the first patient in a study of its lead surgical adhesive product, TissuGlu®. Initiation of the study marks a major milestone in the company's progression of the lead product toward clinical practice.

16 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Biostar Pharmaceuticals to acquire a Xi'an-based medical equipment and nutrients manufacturer for $1.1M

Biostar Pharmaceuticals, Inc., a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has signed a letter of intent ("LOI') with a Xi'an-based medical equipment and nutrients manufacturer ("Acquiree") to acquire 100% of the Acquiree for $1.1 million in cash.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009